References
Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30: 3376–3382.
Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090–1098.
Gilliland DG, Griffin JD . The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532–1542.
Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079–1089.
Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S . A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007; 92: 744–752.
Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 2013; 88: 56–59.
Al-Kali A, Quintas-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T et al. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol 2013; 88: 365–369.
Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004; 18: 466–475.
Horiike S, Misawa S, Nakai H, Kaneko H, Yokota S, Taniwaki M et al. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 1994; 8: 1331–1336.
Dicker F, Haferlach C, Sundermann J, Wendland N, Weiss T, Kern W et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010; 24: 1528–1532.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T et al. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS One 2012; 7: e42334.
Georgiou G, Karali V, Zouvelou C, Kyriakou E, Dimou M, Chrisochoou S et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br J Haematol 2006; 134: 302–306.
Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA et al. Phase II study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013; 121: 4655–4662.
Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008; 22: 538–543.
Acknowledgements
This work was supported by the Ruth and Ken Arnold Fund, the Edward P Evans foundation (GGM and YW), the Celgene Future Leaders in Hematology Award, and Kimberly Patterson Leukemia Research Fellowship (KT). The authors would like to thank Professor Akifumi Takaori at Kyoto University for providing critical review and advice about the project.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Takahashi, K., Jabbour, E., Wang, X. et al. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27, 2081–2083 (2013). https://doi.org/10.1038/leu.2013.165
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.165
- Springer Nature Limited
This article is cited by
-
Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells
Oncogene (2023)
-
Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation
Current Oncology Reports (2020)
-
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Leukemia (2019)
-
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Nature Reviews Cancer (2017)
-
Clonal evolution in myelodysplastic syndromes
Nature Communications (2017)